Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Tang, Z. Fang, Q. Xiu, on Behalf of the Broncho-Vaxom Study Group (Shanghai, China). Efficacy and safety of bacterial lysates in patients with chronic obstructive pulmonary disease and exacerbation. Eur Respir J 2011; 38: Suppl. 55, 3358

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of lasolvan in the treatment of patients with chronic obstructive pulmonary disease Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 The safety of sputum induction in patients with exacerbation of severe and very severe COPD (chronic obstructive pulmonary disease) Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008 The efficacy and treatment length of oral corticosteroids in patient with acute exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005 Efficacy and safety of moxifloxacin in the outpatient treatment of exacerbations of chronic obstructive pulmonary disease Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Bacterial infections in patients with acute exacerbation of chronic obstructive pulmonary diseases Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002 Inferon efficacy in the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD Year: 2008 Efficacy of budesonide/formoterol in Chinese patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Safety and effectiveness of sputum induction in chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 67s Year: 2001 Bacterial infection in acute exacerbations of chronic obstructive pulmonary disease Source: Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections Year: 2012 The impact of using different symptom-based exacerbation algorithms in patients with COPD Source: Eur Respir J 2011; 37: 1260-1268 Year: 2011 Efficacy of azithromycin vs. ciprofloxacin in the treatment of patients with acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 544s Year: 2002 Comparison of the efficacy of azythromycin and roxithromycin in the treatment of acute purulent exacerbation of chronic obstructive pulmonary disease Source: Eur Respir J 2001; 18: Suppl. 33, 138s Year: 2001 Effect of systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 624s Year: 2006 Doxycycline for exacerbations of chronic obstructive pulmonary disease in outpatients: who benefits? Source: ERJ Open Res, 6 (2) 00099-2020; 10.1183/23120541.00099-2020 Year: 2020 Evaluation of bronchodilator responses in chronic obstructive pulmonary disease patients Source: Eur Respir J 2002; 20: Suppl. 38, 247s Year: 2002 Inflammatory markers in patients with acute exacerbation of chronic obstructive pulmonary disease and role of bacterial infection Source: Annual Congress 2010 - Colonisation and infection in COPD Year: 2010 Cardiac biomarkers and outcome in patients with acute exacerbation of chronic obstructive pulmonary disease Source: Annual Congress 2012 - COPD exacerbation Year: 2012 The effect of long-term macrolides therapy for acute exacerbation of chronic obstructive pulmonary disease: A meta-analysis Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Proactive integrated care improves quality of life in patients with COPD Source: Eur Respir J 2009; 33: 1031-1038 Year: 2009 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Source: Eur Respir J 2003; 21: 912 Year: 2003